U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H11N3O4
Molecular Weight 273.2446
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of POMALIDOMIDE

SMILES

c1cc2c(c(c1)N)C(=O)N(C3CCC(=NC3=O)O)C2=O

InChI

InChIKey=UVSMNLNDYGZFPF-UHFFFAOYSA-N
InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/?term=10386948; https://www.ncbi.nlm.nih.gov/pubmed/?term=19009291; http://www.ncbi.nlm.nih.gov/pubmed/?term=12649301; https://www.ncbi.nlm.nih.gov/pubmed/?term=16115943

Pomalidomide is a derivative of thalidomide marketed by Celgene, an analogue of thalidomide, is an immunomodulatory agent with antineoplastic activity. In in vitro cellular assays, pomalidomide inhibited proliferation and induced apoptosis of hematopoietic tumor cells. Additionally, pomalidomide inhibited the proliferation of lenalidomide-resistant multiple myeloma cell lines and synergized with dexamethasone in both lenalidomide-sensitive and lenalidomide-resistant cell lines to induce tumor cell apoptosis. Pomalidomide enhanced T cell- and natural killer (NK) cell-mediated immunity and inhibited production of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. Pomalidomide demonstrated anti-angiogenic activity in a mouse tumor model and in the in vitro umbilical cord model.

CNS Activity

Curator's Comment:: In vitro cell culture experiments were carried out to further investigate the impact of POM on the biology of macrophages. POM crosses the blood brain barrier with CNS penetration of ~ 39%.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
13.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
POMALYST

Approved Use

Indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Launch Date

1.3602816E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
75 ng/mL
4 mg 1 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
POMALIDOMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
860 ng × h/mL
4 mg 1 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
POMALIDOMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.5 h
4 mg 1 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
POMALIDOMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
72%
4 mg 1 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
POMALIDOMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3.4 mg/m2 1 times / day steady, oral
Highest studied dose
Dose: 3.4 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 3.4 mg/m2, 1 times / day
Sources:
unhealthy, 12.3 years (range: 5.8-20.8 years)
n = 29
Health Status: unhealthy
Condition: recurrent, progressive, or refractory CNS tumor
Age Group: 12.3 years (range: 5.8-20.8 years)
Sex: M+F
Population Size: 29
Sources:
DLT: Diarrhea, Thrombocytopenia...
Dose limiting toxicities:
Diarrhea (grade 3, 3 patients)
Thrombocytopenia (grade 3, 3 patients)
Lung infection (grade 3, 3 patients)
Neutropenia (grade 4, 3 patients)
Lung infection (grade 3, 1 patient)
Thrombocytopenia (grade 3, 1 patient)
Sources:
2.6 mg/m2 1 times / day steady, oral
MTD
Dose: 2.6 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 2.6 mg/m2, 1 times / day
Sources:
unhealthy, 12.3 years (range: 5.8-20.8 years)
n = 29
Health Status: unhealthy
Condition: recurrent, progressive, or refractory CNS tumor
Age Group: 12.3 years (range: 5.8-20.8 years)
Sex: M+F
Population Size: 29
Sources:
DLT: Thrombocytopenia...
Dose limiting toxicities:
Thrombocytopenia (grade 4, 1 patient)
Sources:
10 mg 1 times / day steady, oral
Highest studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 56 years (range: 20–85 years)
n = 2
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 56 years (range: 20–85 years)
Sex: M+F
Population Size: 2
Sources:
DLT: Dyspnea, Neutropenia...
Dose limiting toxicities:
Dyspnea (grade 3, 2 patients)
Neutropenia (grade 4, 1 patient)
Sources:
4 mg 1 times / day steady, oral
Recommended|MTD
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 37 - 88 years)
n = 107
Health Status: unhealthy
Condition: relapsed multiple myeloma
Age Group: 61 years (range: 37 - 88 years)
Sex: M+F
Population Size: 107
Sources:
Disc. AE: Birth defects, Venous thromboembolism...
Other AEs: Neutropenia, Anemia...
AEs leading to
discontinuation/dose reduction:
Birth defects (grade 5)
Venous thromboembolism (serious, 3%)
Other AEs:
Neutropenia (grade 3-4, 47%)
Anemia (grade 3-4, 22%)
Thrombocytopenia (grade 3-4, 22%)
Dizziness (grade 3-4, 1%)
Sources:
4 mg 1 times / day steady, oral
MTD
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
unhealthy, 64.7 years (range: 55-72 years)
n = 14
Health Status: unhealthy
Condition: relapsed and refractory multiple myeloma
Age Group: 64.7 years (range: 55-72 years)
Sex: M+F
Population Size: 14
Sources:
DLT: Neutropenia...
Dose limiting toxicities:
Neutropenia (grade 4, 2 patients)
Sources:
2 mg 1 times / day steady, oral
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 64.7 years (range: 55-72 years)
n = 6
Health Status: unhealthy
Condition: relapsed and refractory multiple myeloma
Age Group: 64.7 years (range: 55-72 years)
Sex: M+F
Population Size: 6
Sources:
DLT: Fatigue...
Dose limiting toxicities:
Fatigue (grade 3, 1 patient)
Sources:
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy, 64.7 years (range: 55-72 years)
n = 8
Health Status: unhealthy
Condition: relapsed and refractory multiple myeloma
Age Group: 64.7 years (range: 55-72 years)
Sex: M+F
Population Size: 8
Sources:
DLT: Neutropenia...
Dose limiting toxicities:
Neutropenia (grade 4, 1 patient)
Sources:
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 64.7 years (range: 55-72 years)
n = 10
Health Status: unhealthy
Condition: relapsed and refractory multiple myeloma
Age Group: 64.7 years (range: 55-72 years)
Sex: M+F
Population Size: 10
Sources:
DLT: Neutropenia...
Dose limiting toxicities:
Neutropenia (grade 3-4, 4 patients)
Sources:
50 mg single, oral
Highest studied dose
healthy
n = 30
AEs

AEs

AESignificanceDosePopulation
Lung infection grade 3, 1 patient
DLT
3.4 mg/m2 1 times / day steady, oral
Highest studied dose
Dose: 3.4 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 3.4 mg/m2, 1 times / day
Sources:
unhealthy, 12.3 years (range: 5.8-20.8 years)
n = 29
Health Status: unhealthy
Condition: recurrent, progressive, or refractory CNS tumor
Age Group: 12.3 years (range: 5.8-20.8 years)
Sex: M+F
Population Size: 29
Sources:
Thrombocytopenia grade 3, 1 patient
DLT
3.4 mg/m2 1 times / day steady, oral
Highest studied dose
Dose: 3.4 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 3.4 mg/m2, 1 times / day
Sources:
unhealthy, 12.3 years (range: 5.8-20.8 years)
n = 29
Health Status: unhealthy
Condition: recurrent, progressive, or refractory CNS tumor
Age Group: 12.3 years (range: 5.8-20.8 years)
Sex: M+F
Population Size: 29
Sources:
Diarrhea grade 3, 3 patients
DLT
3.4 mg/m2 1 times / day steady, oral
Highest studied dose
Dose: 3.4 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 3.4 mg/m2, 1 times / day
Sources:
unhealthy, 12.3 years (range: 5.8-20.8 years)
n = 29
Health Status: unhealthy
Condition: recurrent, progressive, or refractory CNS tumor
Age Group: 12.3 years (range: 5.8-20.8 years)
Sex: M+F
Population Size: 29
Sources:
Lung infection grade 3, 3 patients
DLT
3.4 mg/m2 1 times / day steady, oral
Highest studied dose
Dose: 3.4 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 3.4 mg/m2, 1 times / day
Sources:
unhealthy, 12.3 years (range: 5.8-20.8 years)
n = 29
Health Status: unhealthy
Condition: recurrent, progressive, or refractory CNS tumor
Age Group: 12.3 years (range: 5.8-20.8 years)
Sex: M+F
Population Size: 29
Sources:
Thrombocytopenia grade 3, 3 patients
DLT
3.4 mg/m2 1 times / day steady, oral
Highest studied dose
Dose: 3.4 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 3.4 mg/m2, 1 times / day
Sources:
unhealthy, 12.3 years (range: 5.8-20.8 years)
n = 29
Health Status: unhealthy
Condition: recurrent, progressive, or refractory CNS tumor
Age Group: 12.3 years (range: 5.8-20.8 years)
Sex: M+F
Population Size: 29
Sources:
Neutropenia grade 4, 3 patients
DLT
3.4 mg/m2 1 times / day steady, oral
Highest studied dose
Dose: 3.4 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 3.4 mg/m2, 1 times / day
Sources:
unhealthy, 12.3 years (range: 5.8-20.8 years)
n = 29
Health Status: unhealthy
Condition: recurrent, progressive, or refractory CNS tumor
Age Group: 12.3 years (range: 5.8-20.8 years)
Sex: M+F
Population Size: 29
Sources:
Thrombocytopenia grade 4, 1 patient
DLT
2.6 mg/m2 1 times / day steady, oral
MTD
Dose: 2.6 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 2.6 mg/m2, 1 times / day
Sources:
unhealthy, 12.3 years (range: 5.8-20.8 years)
n = 29
Health Status: unhealthy
Condition: recurrent, progressive, or refractory CNS tumor
Age Group: 12.3 years (range: 5.8-20.8 years)
Sex: M+F
Population Size: 29
Sources:
Dyspnea grade 3, 2 patients
DLT
10 mg 1 times / day steady, oral
Highest studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 56 years (range: 20–85 years)
n = 2
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 56 years (range: 20–85 years)
Sex: M+F
Population Size: 2
Sources:
Neutropenia grade 4, 1 patient
DLT
10 mg 1 times / day steady, oral
Highest studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 56 years (range: 20–85 years)
n = 2
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 56 years (range: 20–85 years)
Sex: M+F
Population Size: 2
Sources:
Dizziness grade 3-4, 1%
4 mg 1 times / day steady, oral
Recommended|MTD
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 37 - 88 years)
n = 107
Health Status: unhealthy
Condition: relapsed multiple myeloma
Age Group: 61 years (range: 37 - 88 years)
Sex: M+F
Population Size: 107
Sources:
Anemia grade 3-4, 22%
4 mg 1 times / day steady, oral
Recommended|MTD
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 37 - 88 years)
n = 107
Health Status: unhealthy
Condition: relapsed multiple myeloma
Age Group: 61 years (range: 37 - 88 years)
Sex: M+F
Population Size: 107
Sources:
Thrombocytopenia grade 3-4, 22%
4 mg 1 times / day steady, oral
Recommended|MTD
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 37 - 88 years)
n = 107
Health Status: unhealthy
Condition: relapsed multiple myeloma
Age Group: 61 years (range: 37 - 88 years)
Sex: M+F
Population Size: 107
Sources:
Neutropenia grade 3-4, 47%
4 mg 1 times / day steady, oral
Recommended|MTD
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 37 - 88 years)
n = 107
Health Status: unhealthy
Condition: relapsed multiple myeloma
Age Group: 61 years (range: 37 - 88 years)
Sex: M+F
Population Size: 107
Sources:
Birth defects grade 5
Disc. AE
4 mg 1 times / day steady, oral
Recommended|MTD
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 37 - 88 years)
n = 107
Health Status: unhealthy
Condition: relapsed multiple myeloma
Age Group: 61 years (range: 37 - 88 years)
Sex: M+F
Population Size: 107
Sources:
Venous thromboembolism serious, 3%
Disc. AE
4 mg 1 times / day steady, oral
Recommended|MTD
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 37 - 88 years)
n = 107
Health Status: unhealthy
Condition: relapsed multiple myeloma
Age Group: 61 years (range: 37 - 88 years)
Sex: M+F
Population Size: 107
Sources:
Neutropenia grade 4, 2 patients
DLT
4 mg 1 times / day steady, oral
MTD
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
unhealthy, 64.7 years (range: 55-72 years)
n = 14
Health Status: unhealthy
Condition: relapsed and refractory multiple myeloma
Age Group: 64.7 years (range: 55-72 years)
Sex: M+F
Population Size: 14
Sources:
Fatigue grade 3, 1 patient
DLT
2 mg 1 times / day steady, oral
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 64.7 years (range: 55-72 years)
n = 6
Health Status: unhealthy
Condition: relapsed and refractory multiple myeloma
Age Group: 64.7 years (range: 55-72 years)
Sex: M+F
Population Size: 6
Sources:
Neutropenia grade 4, 1 patient
DLT
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy, 64.7 years (range: 55-72 years)
n = 8
Health Status: unhealthy
Condition: relapsed and refractory multiple myeloma
Age Group: 64.7 years (range: 55-72 years)
Sex: M+F
Population Size: 8
Sources:
Neutropenia grade 3-4, 4 patients
DLT
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 64.7 years (range: 55-72 years)
n = 10
Health Status: unhealthy
Condition: relapsed and refractory multiple myeloma
Age Group: 64.7 years (range: 55-72 years)
Sex: M+F
Population Size: 10
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >30 uM]
no [IC50 >30 uM]
no [IC50 >30 uM]
no [IC50 >30 uM]
no [IC50 >30 uM]
no [IC50 >30 uM]
no [IC50 >30 uM]
no [IC50 >30 uM]
no [IC50 >30 uM]
no [Inhibition 20 uM]
no [Inhibition 20 uM]
no [Inhibition 20 uM]
no
no
no
no
no
no
no
no
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
unknown
Comment: Clinical DDI studies to assess the influence of CYP3A4, CYP1A2 and P-gp inhibitors on pomalidomide exposure and any metabolites is planned
Page: 4.0
major
unknown
Comment: Clinical DDI studies to assess the influence of CYP3A4, CYP1A2 and P-gp inhibitors on pomalidomide exposure and any metabolites is planned
Page: 4.0
minor
minor
yes
yes
unknown
Comment: Clinical DDI studies to assess the influence of CYP3A4, CYP1A2 and P-gp inhibitors on pomalidomide exposure and any metabolites is planned
Page: 6.0
PubMed

PubMed

TitleDatePubMed
S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
2002 Apr 15
Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis.
2005 May 15
Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain.
2005 Sep
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.
2006 Apr 15
Primary function analysis of human mental retardation related gene CRBN.
2008 Jun
Identification of a primary target of thalidomide teratogenicity.
2010 Mar 12
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
2012 Nov
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma.
2013
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
2013 Apr
Pomalidomide and myeloma meningitis.
2013 Apr
Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist.
2013 Jun
Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.
2014 Aug 7
Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.
2014 Jan 21
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Should be given in combination with dexamethasone
4 mg per day taken orally on Days 1-21 of repeated 28­ day cycles until disease progression
Route of Administration: Oral
When a PBMC population was maintained in IL-2 over a period of 7 days, the addition of pomalidomide 1 μM (IC50) in the incubation significantly decreased the proportion/number of Tregs in the population, compared with untreated controls.
Name Type Language
POMALIDOMIDE
DASH   EMA EPAR   INN   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
ACTIMID
Brand Name English
POMALIDOMIDE [USAN]
Common Name English
POMALIDOMIDE [INN]
Common Name English
IMID 3
Code English
1H-ISOINDOLE-1,3(2H)-DIONE, 4-AMINO-2-(2,6-DIOXO-3-PIPERIDINYL)-
Systematic Name English
IMNOVID
Brand Name English
POMALIDOMIDE [JAN]
Common Name English
IMID-3
Code English
CC-4047
Code English
4-AMINO-2-((3RS)-2,6-DIOXOPIPERIDIN-3-YL)-1H-ISOINDOLE-1,3(2H)-DIONE
Systematic Name English
POMALIDOMIDE [ORANGE BOOK]
Common Name English
POMALIDOMIDE [MI]
Common Name English
POMALIDOMIDE [VANDF]
Common Name English
POMALIDOMIDE [WHO-DD]
Common Name English
3-(3-AMINO)-PHTALAMIDO-GLUTARIMIDE
Common Name English
POMALIDOMIDE [EMA EPAR]
Common Name English
POMALYST
Brand Name English
Classification Tree Code System Code
WHO-VATC QL04AX06
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
FDA ORPHAN DRUG 308610
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
FDA ORPHAN DRUG 635818
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
EU-Orphan Drug EU/3/10/759
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
FDA ORPHAN DRUG 161402
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
FDA ORPHAN DRUG 363212
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
NCI_THESAURUS C129820
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
NCI_THESAURUS C54677
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
WHO-ATC L04AX06
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
NDF-RT N0000184014
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
NCI_THESAURUS C1742
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
Code System Code Type Description
IUPHAR
7348
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY
MESH
C467566
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY
HSDB
8222
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY
FDA UNII
D2UX06XLB5
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY
PUBCHEM
134780
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY
DRUG BANK
DB08910
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY
LACTMED
Pomalidomide
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY
EVMPD
SUB33379
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY
MERCK INDEX
M8978
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY Merck Index
RXCUI
1369713
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
POMALIDOMIDE
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY
NCI_THESAURUS
C72560
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY
INN
8873
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY
DRUG CENTRAL
4746
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY
ChEMBL
CHEMBL43452
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY
JAPANESE REVIEW
POMALYST
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY APPROVED MARCH 2015
CAS
19171-19-8
Created by admin on Sat Jun 26 02:05:01 UTC 2021 , Edited by admin on Sat Jun 26 02:05:01 UTC 2021
PRIMARY